Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Double-blind, Multicenter Phase II Clinical Trial to Evaluate the Efficacy and Safety of Therapeutic Hepatitis B Vaccine (Mimogen-based) Joint Entecavir in Treating HBeAg Positive Chronic Hepatitis B Patients

NCT01326546 is registered in ClinicalTrials.gov with Chongqing Jiachen Biotechnology Ltd. as lead sponsor.

NCT NCT01326546
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01326546 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Double-blind, Multicenter Phase II Clinical Trial to Evaluate the Efficacy and Safety of Therapeutic Hepatitis B Vaccine (Mimogen-based) Joint Entecavir in Treating HBeAg Positive Chronic Hepatitis B Patients
Lead sponsor
Chongqing Jiachen Biotechnology Ltd.
Phase
Phase 2
Overall status
Completed
Start date
June 30, 2010
Completion date
January 31, 2014
Enrollment
378 (actual)
Sites
15

Conditions

As the registry lists them; a condition with its own page is linked.

chronic hepatitis b